TNF Biosimilars Market Size, Share & Trends Analysis Report By Drug (Adalimumab Biosimilar, Infliximab Biosimilar, Certolizumab Biosimilar, Etanercept Biosimilar, and Golimumab Biosimilar), By Distribution Channel (Online Pharmacy, Hospital Pharmacy, Retail Pharmacy), Region And Segment Forecasts, 2025-2034
Segmentation of TNF Biosimilars Market
Global TNF Biosimilars Market Outlook, by Drug
- Adalimumab biosimilar
- Amjevita
- Yusimry
- Cyltezo
- Exemptia
- Others (Products approved in developing countries & pipeline products)
- Infliximab biosimilar
- Avsola (infliximab-axxq)
- Flixabi (SB2)
- Inflectra (infliximab-dyyb)
- Zessly
- Others (Products approved in developing countries & pipeline products)
- Certolizumab biosimilar
- Etanercept biosimilar
- Benepali
- Nepexto
- Eticovo
- Erelzi
- Others (Products approved in developing countries & pipeline products)
- Golimumab biosimilar
Global TNF Biosimilars Market Outlook, by Application
- Rheumatoid Arthritis
- Psoriasis
- Inflammatory Bowel Disease
- Ankylosing Spondylitis
- Others
Global TNF Biosimilars Market Outlook, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global TNF Biosimilars Market Outlook By Region
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- North America
- U.S.
- Canada
- Asia Pacific
- India
- China
- Japan
- South Korea
- Australia & New Zealand
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global TNF Biosimilars Market Snapshot
Chapter 4. Global TNF Biosimilars Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global TNF Biosimilars Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on TNF Biosimilars Market Industry Trends
Chapter 5. TNF Biosimilars Market Segmentation 1: By Drug, Estimates & Trend Analysis
5.1. Market Share by Drug, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug:
5.2.1. Adalimumab biosimilar
5.2.1.1. Amjevita
5.2.1.2. Yusimry
5.2.1.3. Cyltezo
5.2.1.4. Exemptia
5.2.1.5. Others (Products approved in developing countries & pipeline products)
5.2.2. Infliximab biosimilar
5.2.2.1. Avsola (infliximab-axxq)
5.2.2.2. Flixabi (SB2)
5.2.2.3. Inflectra (infliximab-dyyb)
5.2.2.4. Zessly
5.2.2.5. Others (Products approved in developing countries & pipeline products)
5.2.3. Certolizumab biosimilar
5.2.4. Etanercept biosimilar
5.2.4.1. Benepali
5.2.4.2. Nepexto
5.2.4.3. Eticovo
5.2.4.4. Erelzi
5.2.4.5. Others (Products approved in developing countries & pipeline products)
5.2.5. Golimumab biosimilar
Chapter 6. TNF Biosimilars Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
6.2.1. Rheumatoid Arthritis
6.2.2. Psoriasis
6.2.3. Inflammatory Bowel Disease
6.2.4. Ankylosing Spondylitis
6.2.5. Others
Chapter 7. TNF Biosimilars Market Segmentation 3: By Distribution Channel, Estimates & Trend Analysis
7.1. Market Share by Distribution Channel, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
7.2.1. Hospital Pharmacy
7.2.2. Retail Pharmacy
7.2.3. Online Pharmacy
7.2.4. Others
Chapter 8. TNF Biosimilars Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global TNF Biosimilars Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Drug, 2021-2034
8.2.3. North America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.2.4. North America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.3. Europe
8.3.1. Europe TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Drug, 2021-2034
8.3.3. Europe TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.3.4. Europe TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Drug, 2021-2034
8.4.3. Asia Pacific TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.4.4. Asia Pacific TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.5. Latin America
8.5.1. Latin America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Drug, 2021-2034
8.5.3. Latin America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.5.4. Latin America TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Drug, 2021-2034
8.6.3. Middle East & Africa TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.6.4. Middle East & Africa TNF Biosimilars Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Alvotech
9.2.1.1. Business Overview
9.2.1.2. Key Product/Service
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Amgen
9.2.3. Amgen Inc.
9.2.4. AYUMI Pharmaceutica
9.2.5. Biocon
9.2.6. Biogen
9.2.7. Biosimilar Collaborations Ireland Limited
9.2.8. Boeheringer Ingelheim
9.2.9. Celltrion
9.2.10. Cipla
9.2.11. Coherus Biosciences
9.2.12. Cordavis Ltd.
9.2.13. Epirus Biopharmaceuticals
9.2.14. Fresenius Kabi
9.2.15. Glenmark Pharmaceuticals
9.2.16. Hanwha Chemical
9.2.17. Hetero
9.2.18. Innovent Biologics
9.2.19. Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics)
9.2.20. LG Chem
9.2.21. Lupin
9.2.22. Mabpharm
9.2.23. Merck
9.2.24. Mylan
9.2.25. Nichi-Iko Pharmaceutical
9.2.26. Organon & Co.
9.2.27. Pfizer
9.2.28. Ranbaxy Laboratories (now Sun Pharma)
9.2.29. Samsung Bioepis
9.2.30. Sandoz
9.2.31. Shanghai CP Guojian Pharmaceutical
9.2.32. Sorrento Therapeutics (partner)
9.2.33. Stada Arzneimittel AG
9.2.34. Sunshine Guojian Pharmaceutical
9.2.35. Synermore
9.2.36. Teva
9.2.37. Torrent Pharmaceuticals
9.2.38. YL Biologics
9.2.39. Zydus Cadila
9.2.40. Other prominent players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
The TNF Biosimilars Market is expected to grow at a 16.5% CAGR during the forecast period for 2025-2034.
Alvotech, Amgen, Amgen Inc., AYUMI Pharmaceutica, Biocon, Biogen, Biosimilar Collaborations Ireland Limited, Boehringer Ingelheim, Celltrion, Cipla, C
Drugs, Application and distribution channel are the key segments of the TNF Biosimilars Market.
Europe is leading the TNF Biosimilars Market.